JPH01163130A - 腫瘍抗原およびアジュバントを含有するワクチン - Google Patents

腫瘍抗原およびアジュバントを含有するワクチン

Info

Publication number
JPH01163130A
JPH01163130A JP63244691A JP24469188A JPH01163130A JP H01163130 A JPH01163130 A JP H01163130A JP 63244691 A JP63244691 A JP 63244691A JP 24469188 A JP24469188 A JP 24469188A JP H01163130 A JPH01163130 A JP H01163130A
Authority
JP
Japan
Prior art keywords
tumor
acid
pyridine
microorganism
cell wall
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP63244691A
Other languages
English (en)
Japanese (ja)
Other versions
JPH0575731B2 (cg-RX-API-DMAC10.html
Inventor
John L Cantrell
ジョン　レオナード　カントレル
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ribi Immunochem Research Inc
Original Assignee
Ribi Immunochem Research Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ribi Immunochem Research Inc filed Critical Ribi Immunochem Research Inc
Publication of JPH01163130A publication Critical patent/JPH01163130A/ja
Publication of JPH0575731B2 publication Critical patent/JPH0575731B2/ja
Granted legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55544—Bacterial toxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/5555—Muramyl dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55588—Adjuvants of undefined constitution
    • A61K2039/55594—Adjuvants of undefined constitution from bacteria

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
JP63244691A 1987-09-30 1988-09-30 腫瘍抗原およびアジュバントを含有するワクチン Granted JPH01163130A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US07/102,909 US4877611A (en) 1986-04-15 1987-09-30 Vaccine containing tumor antigens and adjuvants
US102909 1987-09-30

Publications (2)

Publication Number Publication Date
JPH01163130A true JPH01163130A (ja) 1989-06-27
JPH0575731B2 JPH0575731B2 (cg-RX-API-DMAC10.html) 1993-10-21

Family

ID=22292343

Family Applications (1)

Application Number Title Priority Date Filing Date
JP63244691A Granted JPH01163130A (ja) 1987-09-30 1988-09-30 腫瘍抗原およびアジュバントを含有するワクチン

Country Status (10)

Country Link
US (1) US4877611A (cg-RX-API-DMAC10.html)
JP (1) JPH01163130A (cg-RX-API-DMAC10.html)
BE (1) BE1001634A4 (cg-RX-API-DMAC10.html)
CA (1) CA1333152C (cg-RX-API-DMAC10.html)
CH (1) CH678492A5 (cg-RX-API-DMAC10.html)
DE (1) DE3833319A1 (cg-RX-API-DMAC10.html)
FR (1) FR2620941B1 (cg-RX-API-DMAC10.html)
GB (1) GB2210557B (cg-RX-API-DMAC10.html)
IT (1) IT1226861B (cg-RX-API-DMAC10.html)
NL (1) NL8802393A (cg-RX-API-DMAC10.html)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008214266A (ja) * 2007-03-05 2008-09-18 Dainippon Sumitomo Pharma Co Ltd 細菌細胞壁骨格成分の製造方法
JP2013531677A (ja) * 2010-07-02 2013-08-08 インターベツト・インターナシヨナル・ベー・ベー エーリキア・カニスに対するワクチンおよび関連する方法

Families Citing this family (224)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH05503837A (ja) * 1987-12-09 1993-06-24 ザ・ジェネラル・ホスピタル・コーポレーション 癌関連抗原およびその抗原を認識する抗体
US5212085A (en) * 1987-12-09 1993-05-18 The General Hospital Corporation Sf-25 colon adenocarcinoma antigen, and antibodies with recognize this antigen
DE3922444A1 (de) * 1988-03-01 1991-01-10 Deutsches Krebsforsch Virusmodifizierte tumorvakzine fuer die immuntherapie von tumormetastasen
US6093406A (en) * 1988-06-02 2000-07-25 The United States Of America As Represented By The Secretary Of The Army Vaccine for induction of immunity to malaria
WO1990003183A1 (en) * 1988-09-23 1990-04-05 University Of Southern California Immunotherapy vaccine for melanoma tumors
US4963364A (en) * 1989-04-10 1990-10-16 Fox Sidney W Microencapsulated antitumor agent
DE69031120T2 (de) * 1989-05-19 1998-01-15 Genentech, Inc., South San Francisco, Calif. Her2 extrazellulare domäne
US6177083B1 (en) * 1990-07-26 2001-01-23 Evax Technologies Gmbh Process for the production of vaccines and their use
EP0477050B1 (en) * 1990-08-20 1997-05-21 Gen-Ichiro Soma LPS-producing bacteria, LPSs, and LPS-containing medicines and veterinary medicines
US5413993A (en) * 1991-08-20 1995-05-09 Gen-Ichiro Soma Method for the treatment of narcotic withdrawal symptoms in animals using lipopolysaccharides
GB9105992D0 (en) * 1991-03-21 1991-05-08 Smithkline Beecham Biolog Vaccine
US5709860A (en) * 1991-07-25 1998-01-20 Idec Pharmaceuticals Corporation Induction of cytotoxic T-lymphocyte responses
US6197311B1 (en) * 1991-07-25 2001-03-06 Idec Pharmaceuticals Corporation Induction of cytotoxic T-lymphocyte responses
AU660325B2 (en) * 1991-10-11 1995-06-22 Eisai Co. Ltd. Anti-endotoxin compounds and related molecules and methods
US5530113A (en) * 1991-10-11 1996-06-25 Eisai Co., Ltd. Anti-endotoxin compounds
KR100278157B1 (ko) * 1992-06-25 2001-01-15 장 스테판느 보조약을 함유하는 백신 조성물
AU6409894A (en) * 1993-03-16 1994-10-11 Samuel Bogoch Recognin vaccines
CZ289476B6 (cs) * 1993-03-23 2002-01-16 Smithkline Beecham Biologicals (S.A.) Očkovací přípravek a způsob jeho výroby
JPH09504000A (ja) * 1993-08-11 1997-04-22 ジェナー テクノロジーズ 前立腺癌ワクチン
CA2261433A1 (en) * 1993-12-09 1995-06-10 Belinda Sanchez Ramirez Composition comprising autologous epidermal growth factor
USD365131S (en) 1994-05-25 1995-12-12 Royal Grip, Inc. Golf club grip
US6218166B1 (en) * 1994-12-09 2001-04-17 John Wayne Cancer Institute Adjuvant incorporation into antigen carrying cells: compositions and methods
FR2733151B1 (fr) * 1995-04-20 1997-05-23 Seppic Sa Composition therapeutique comprenant un antigene ou un generateur in vivo d'un compose comprenant une sequence d'acides amines
US6117432A (en) * 1995-04-20 2000-09-12 Societe D'exploitation De Produits Pour Les Industries Chimiques (S.E.P.P.I.C.) Therapeutic composition comprising an antigen or an in vivo generator of a compound comprising an amino acid sequence
US6689370B1 (en) 1995-04-20 2004-02-10 Societe D'exploitation De Produits Pour Les Industries Chimiques (S.E.P.P.I.C.) Therapeutic composition comprising an antigen or an in vivo generator of a compound comprising an amino acid sequence
US6458366B1 (en) 1995-09-01 2002-10-01 Corixa Corporation Compounds and methods for diagnosis of tuberculosis
US6592877B1 (en) * 1995-09-01 2003-07-15 Corixa Corporation Compounds and methods for immunotherapy and diagnosis of tuberculosis
US6290969B1 (en) * 1995-09-01 2001-09-18 Corixa Corporation Compounds and methods for immunotherapy and diagnosis of tuberculosis
US6406689B1 (en) 1995-10-03 2002-06-18 Frank W. Falkenberg Compositions and methods for treatment of tumors and metastatic diseases
US6303584B1 (en) * 1996-11-20 2001-10-16 The University Of Montana Water soluble lipidated arabinogalactan
US7087713B2 (en) * 2000-02-25 2006-08-08 Corixa Corporation Compounds and methods for diagnosis and immunotherapy of tuberculosis
BR9815602A (pt) 1997-08-05 2001-12-11 Bioniche Inc Composição e processo para induzir uma respostaem células sensìveis de um animal para tratar umcancer
US20020147143A1 (en) 1998-03-18 2002-10-10 Corixa Corporation Compositions and methods for the therapy and diagnosis of lung cancer
US6280742B1 (en) 1998-06-17 2001-08-28 Zonagen, Inc. Methods and materials for the treatment of prostatic carcinoma
CA2337445A1 (en) * 1998-07-16 2000-01-27 Sumitomo Pharmaceuticals Co., Ltd. Preparations for immunotherapy for cancer having bacterial somatic constituent as the active ingredient
DK2272859T3 (en) 1998-08-07 2015-01-19 Univ Washington Immunological herpes simplex virus antigens and methods for their use
US20030235557A1 (en) 1998-09-30 2003-12-25 Corixa Corporation Compositions and methods for WT1 specific immunotherapy
US20010033839A1 (en) * 1999-10-04 2001-10-25 Emilio Barbera-Guillem Vaccine and immunotherapy for solid nonlymphoid tumor and related immune dysregulation
TR200102500T2 (tr) 1998-12-08 2002-03-21 Corixa Corporation Chlamydia enfeksiyonunu tedavi etmek i‡in bileçikler.
US20020119158A1 (en) 1998-12-17 2002-08-29 Corixa Corporation Compositions and methods for the therapy and diagnosis of ovarian cancer
US6579973B1 (en) 1998-12-28 2003-06-17 Corixa Corporation Compositions for the treatment and diagnosis of breast cancer and methods for their use
EA005140B1 (ru) 1999-04-02 2004-12-30 Корикса Корпорейшн Соединения и способы для лечения и диагностики рака легкого
US8143386B2 (en) * 1999-04-07 2012-03-27 Corixa Corporation Fusion proteins of mycobacterium tuberculosis antigens and their uses
WO2001024820A1 (en) * 1999-10-07 2001-04-12 Corixa Corporation Fusion proteins of mycobacterium tuberculosis
RU2152800C1 (ru) * 1999-12-08 2000-07-20 Зыбин Дмитрий Владимирович Способ культивирования и модификации гетерогенных клеток млекопитающих
DE60043759D1 (de) * 1999-12-13 2010-03-11 Bioniche Life Sciences Inc Therapeutisch nützliche synthetische Oligonukleotide
EP1250152B1 (en) * 1999-12-28 2013-05-15 Bioniche Urology IP Inc. Synergistic composition containing hyaluronic acid in the treatment of cancer
KR100848973B1 (ko) 2000-02-23 2008-07-30 글락소스미스클라인 바이오로지칼즈 에스.에이. 종양 특이적 동물 단백질
US20040002068A1 (en) 2000-03-01 2004-01-01 Corixa Corporation Compositions and methods for the detection, diagnosis and therapy of hematological malignancies
ES2303525T3 (es) 2000-04-21 2008-08-16 Corixa Corporation Compuestos y metodos para el tratamiento y diagnostico de infeccion por chlamydia.
ES2305086T3 (es) 2000-05-19 2008-11-01 Corixa Corporation Tratamiento profilactico y terapeutico de enfermedades alergicas, autoinmunes e infecciosas con compuestos con base de monosacaridos.
US20030139356A1 (en) 2001-05-18 2003-07-24 Persing David H. Prophylactic and therapeutic treatment of infectious and other diseases with mono- and disaccharide-based compounds
EP2133100B1 (en) * 2000-06-20 2011-10-05 Corixa Corporation MTB32A Antigen of mycobacterium tuberculosis with inactivated active site and fusion proteins thereof
EP1319069B1 (en) 2000-06-28 2008-05-21 Corixa Corporation Compositions and methods for the therapy and diagnosis of lung cancer
US8568766B2 (en) 2000-08-24 2013-10-29 Gattadahalli M. Anantharamaiah Peptides and peptide mimetics to treat pathologies associated with eye disease
RU2192884C2 (ru) * 2000-11-09 2002-11-20 Государственное учреждение Научно-исследовательский институт клинической иммунологии СО РАМН Вакцина для стимуляции противоопухолевого иммунитета
GB0105360D0 (en) * 2001-03-03 2001-04-18 Glaxo Group Ltd Chimaeric immunogens
DE10112851C1 (de) * 2001-03-16 2002-10-10 Gsf Forschungszentrum Umwelt Semi-allogene Antitumor-Vakzine mit HLA-haplo-identischen Antigen-präsentierenden Zellen
CU22999A1 (es) * 2001-12-04 2004-10-12 Centro Inmunologia Molecular Método de tratamiento de enfermedades malignas e infecciosas crónicas
WO2002089747A2 (en) 2001-05-09 2002-11-14 Corixa Corporation Compositions and methods for the therapy and diagnosis of prostate cancer
DE10132502A1 (de) * 2001-07-05 2003-01-23 Gsf Forschungszentrum Umwelt Angriff auf Tumorzellen mit fehlender, niedriger oder anormaler MHC-Expression durch kombinieren von nicht MHC-Restringierten T-Zellen/NK-Zellen und MHC-Restringierten Zellen
CA2452382A1 (en) 2001-07-10 2003-01-23 Corixa Corporation Compositions and methods for delivery of proteins and adjuvants encapsulated in microspheres
MXPA04002631A (es) * 2001-09-20 2004-07-08 Glaxo Group Ltd Vacunas de adn optimizadas por codon gag-vih.
WO2003028758A1 (en) * 2001-09-28 2003-04-10 Haruo Sugiyama Novel method of inducing antigen-specific t cells
US20030215460A1 (en) * 2002-05-07 2003-11-20 Schall Thomas J. Methods and compositions for inducing an immune response
US20030157101A1 (en) * 2001-11-15 2003-08-21 Carlo Gambacorti-Passerini Immunogenic ALK peptides
EP1581119B1 (en) 2001-12-17 2013-01-30 Corixa Corporation Compositions and methods for the therapy and diagnosis of inflammatory bowel disease
AU2003213118A1 (en) 2002-02-15 2003-09-09 Corixa Corporation Fusion proteins of mycobacterium tuberculosis
WO2003073827A2 (en) * 2002-02-28 2003-09-12 Corixa Corporation Methods of modulating dendritic cells using adjuvants
US20030224013A1 (en) * 2002-04-19 2003-12-04 Cole Garry T. Methods for protection against Coccidioides spp. infection using Coccidioides spp. urea amidohydrolase (Ure) protein
EP2865386B1 (en) 2002-07-18 2017-07-05 University of Washington Pharmaceutical compositions comprising immunologically active herpes simplex virus (HSV) protein fragments
WO2004012751A1 (ja) * 2002-08-02 2004-02-12 Sumitomo Pharmaceuticals Company, Limited 細菌細胞壁骨格成分製剤
AU2003290825C1 (en) * 2002-11-13 2009-12-10 The Uab Research Foundation Synthetic single domain polypeptides mimicking apolipoprotein E and methods of use
RU2389732C2 (ru) 2003-01-06 2010-05-20 Корикса Корпорейшн Некоторые аминоалкилглюкозаминидфосфатные производные и их применение
US7960522B2 (en) 2003-01-06 2011-06-14 Corixa Corporation Certain aminoalkyl glucosaminide phosphate compounds and their use
WO2005071058A2 (en) * 2004-01-27 2005-08-04 Compugen Ltd. Methods and systems for annotating biomolecular sequences
CA2564180A1 (en) * 2004-04-22 2005-11-03 Dainippon Sumitomo Pharma Co., Ltd. Pharmaceutical preparation containing bacterial cell wall skeleton component
CA2837748C (en) 2004-05-25 2016-03-08 Oregon Health And Science University Siv and hiv vaccination using rhcmv-and hcmv-based vaccine vectors
WO2005117958A1 (en) 2004-05-28 2005-12-15 Glaxosmithkline Biologicals S.A. Vaccine compositions comprising virosomes and a saponin adjuvant
CA2587084C (en) 2004-10-08 2019-07-16 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services, Centers For Disease Control And Prevention Modulation of replicative fitness by using less frequently used synonym ous codons
WO2006065549A2 (en) 2004-12-03 2006-06-22 Medical University Of Ohio Attenuated vaccine useful for immunizations against coccidioides spp. infections
GB0427131D0 (en) * 2004-12-10 2005-01-12 Glaxosmithkline Biolog Sa Novel combination
KR20070121814A (ko) 2005-03-31 2007-12-27 글락소스미스클라인 바이오로지칼즈 에스.에이. 클라미디아 감염에 대비한 백신
ES2524572T3 (es) 2005-04-29 2014-12-10 Glaxosmithkline Biologicals S.A. Procedimiento novedoso de prevención o tratamiento de infección por M. tuberculosis
CA2616026A1 (en) * 2005-07-22 2007-02-08 Research Development Foundation Attenuated strains of flaviviruses , and uses thereof
RU2483751C2 (ru) 2005-10-18 2013-06-10 Новавакс, Инк. ФУНКЦИОНАЛЬНЫЕ ВИРУСОПОДОБНЫЕ ЧАСТИЦЫ ГРИППА (VLPs)
US7622128B2 (en) * 2005-12-13 2009-11-24 University Of Washington Porphyromonas gingivalis 1435/1449 LPS as an immune modulator
TWI457133B (zh) 2005-12-13 2014-10-21 Glaxosmithkline Biolog Sa 新穎組合物
WO2007082105A2 (en) 2006-01-16 2007-07-19 Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Chlamydia vaccine
US8128921B2 (en) * 2006-07-11 2012-03-06 University Of Connecticut Use of conditional plasmodium strains lacking nutrient transporters in malaria vaccination
US8153116B2 (en) 2006-07-11 2012-04-10 University Of Connecticut Use of conditional plasmodium strains lacking an essential gene in malaria vaccination
US20090181078A1 (en) 2006-09-26 2009-07-16 Infectious Disease Research Institute Vaccine composition containing synthetic adjuvant
EP2486938B1 (en) 2006-09-26 2018-05-09 Infectious Disease Research Institute Vaccine composition containing synthetic adjuvant
MX351247B (es) 2007-04-04 2017-10-05 Infectious Disease Res Institute Star Composiciones inmunogenicas que comprenden polipeptidos de mycobacterium tuberculosis y fusiones de los mismos.
TW200908994A (en) 2007-04-20 2009-03-01 Glaxosmithkline Biolog Sa Vaccine
WO2009006479A2 (en) 2007-07-02 2009-01-08 Etubics Corporation Methods and compositions for producing an adenovirus vector for use with multiple vaccinations
HUE025702T2 (en) 2007-07-19 2016-04-28 Novavax Inc Avian Flu Chimeric VLPs
EP2682400B1 (en) 2007-08-28 2017-09-20 Uab Research Foundation Synthetic apolipoprotein E mimicking polypeptides and methods of use
JP2010537638A (ja) 2007-08-28 2010-12-09 ユーエービー リサーチ ファウンデーション 合成アポリポ蛋白質ｅ模倣ポリペプチドおよび使用方法
US20090215710A1 (en) * 2007-09-24 2009-08-27 Reliance Life Sciences Pvt. Ltd. Carbohydrate based toll-like receptor (tlr) antagonists
US20090215908A1 (en) * 2007-09-24 2009-08-27 Reliance Life Sciences Pvt. Ltd. Toll like receptor (tlr) signaling antagonist
NZ585556A (en) 2007-11-07 2012-07-27 Celldex Therapeutics Inc Antibodies that bind human dendritic and epithelial cell 205 (dec-205)
PL2222710T3 (pl) 2007-12-24 2017-01-31 Id Biomedical Corporation Of Quebec Rekombinowane antygeny rsv
EP2245055A2 (en) * 2008-01-31 2010-11-03 Compugen Ltd. Polypeptides and polynucleotides, and uses thereof as a drug target for producing drugs and biologics
CA2721506C (en) 2008-04-16 2019-09-17 Jun Luo Compositions and methods for treating or preventing prostate cancer and for detecting androgen receptor variants
JP2011528222A (ja) * 2008-07-18 2011-11-17 アイディー バイオメディカル コーポレイション オブ ケベック キメラ呼吸器合胞体ウイルスポリペプチド抗原
DK2352756T3 (da) 2008-11-24 2012-12-03 Helmholtz Zentrum Muenchen Højaffin T-cellereceptor og anvendelse af denne
MY161495A (en) 2008-11-26 2017-04-14 Government Of The Us Secretary Dept Of Health And Human Services Virus like particle compositions and methods of use
EP2370099B1 (en) 2008-12-09 2016-04-20 Novavax, Inc. Modified rsv f proteins and methods of their use
BRPI1011224A2 (pt) 2009-02-17 2016-03-15 Glaxosmithkline Biolog Sa vacina contra vírus da dengue inativado com adjuvante livre de alumínio
MX360448B (es) 2009-06-05 2018-11-01 Infectious Disease Res Inst Adyuvantes sinteticos de glucopiranosil-lipido.
MX2012000036A (es) 2009-06-24 2012-02-28 Glaxosmithkline Biolog Sa Vacuna.
PL2445526T3 (pl) 2009-06-24 2017-08-31 Glaxosmithkline Biologicals S.A. Rekombinowane antygeny rsv
WO2011005772A1 (en) 2009-07-06 2011-01-13 Variation Biotechnologies, Inc. Methods for preparing vesicles and formulations produced therefrom
EP2451950B9 (en) 2009-07-06 2016-11-23 Variation Biotechnologies Inc. Methods for preparing vesicles and formulations produced therefrom
EP3178490B1 (en) 2009-07-15 2022-04-20 GlaxoSmithKline Biologicals S.A. Rsv f protein compositions and methods for making same
GB0919117D0 (en) 2009-10-30 2009-12-16 Glaxosmithkline Biolog Sa Process
KR101125764B1 (ko) 2010-01-27 2012-03-27 백태현 항산균 세포벽골격을 이용한 백신매개체 및 그에 의한 백신의 제조 방법
CN103154034B (zh) 2010-04-13 2016-06-08 塞尔德克斯医疗公司 结合人cd27的抗体及其用途
CA2840079C (en) 2010-07-06 2018-07-03 Variation Biotechnologies Inc. Compositions and methods for treating influenza
KR20130140009A (ko) 2010-10-15 2013-12-23 글락소스미스클라인 바이오로지칼즈 에스.에이. 사이토메갈로바이러스 ｇｂ 항원
US20130345079A1 (en) 2010-10-27 2013-12-26 Infectious Disease Research Institute Mycobacterium tuberculosis antigens and combinations thereof having high seroreactivity
JP6158088B2 (ja) 2010-11-05 2017-07-05 ノババックス，インコーポレイテッド 狂犬病糖タンパク質ウイルス様粒子（ｖｌｐ）
BR112013011420A2 (pt) 2010-11-08 2016-08-02 Infectious Disease Res Inst vacinas compreendendo poliptídeos de nucleosídeo hidrolase não específica e esterol 24-c-metil-transferase (smt) para o tratamento e o diagnóstico de leishmaníase
EP3023106B1 (en) 2010-12-14 2019-07-31 GlaxoSmithKline Biologicals S.A. Mycobacterium antigenic composition
CN103501811B (zh) 2011-01-13 2016-03-30 变异生物技术公司 用于治疗病毒感染的组合物和方法
US9487563B2 (en) 2011-01-31 2016-11-08 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Virus-like particles and methods of use
GB201106357D0 (en) 2011-04-14 2011-06-01 Pessi Antonello Composition and uses thereof
EA027236B1 (ru) 2011-04-08 2017-07-31 Иммьюн Дизайн Корп. Иммуногенные композиции и способы применения таких композиций для индукции гуморального и клеточного иммунного ответа
SI3275892T1 (sl) 2011-05-13 2020-06-30 Glaxosmithkline Biologicals S.A. Prefuzijski RSV F antigeni
EP2723365A1 (en) 2011-06-21 2014-04-30 Oncofactor Corporation Compositions and methods for the therapy and diagnosis of cancer
GB201113570D0 (en) 2011-08-05 2011-09-21 Glaxosmithkline Biolog Sa Vaccine
GB201116248D0 (en) 2011-09-20 2011-11-02 Glaxosmithkline Biolog Sa Liposome production using isopropanol
GB201119999D0 (en) 2011-11-20 2012-01-04 Glaxosmithkline Biolog Sa Vaccine
GB201120000D0 (en) 2011-11-20 2012-01-04 Glaxosmithkline Biolog Sa Vaccine
CA2894442C (en) 2012-01-12 2020-01-21 Variation Biotechnologies Inc. Compositions and methods for treating viral infections
EP4008354A1 (en) 2012-01-27 2022-06-08 Variation Biotechnologies Inc. Methods and compositions for therapeutic agents
EP2827891A1 (en) 2012-03-18 2015-01-28 GlaxoSmithKline Biologicals S.A. Method of vaccination against human papillomavirus
ES2673556T3 (es) 2012-05-16 2018-06-22 Immune Design Corp. Vacunas para el VHS-2
EP2666785A1 (en) 2012-05-23 2013-11-27 Affiris AG Complement component C5a-based vaccine
PT2879701T (pt) 2012-08-03 2024-02-12 Access To Advanced Health Inst Composições e métodos para o tratamento de uma infeção ativa por mycobacterium tuberculosis
SG11201500573RA (en) 2012-08-06 2015-02-27 Glaxosmithkline Biolog Sa Method for eliciting in infants an immune response against rsv and b. pertussis
US20140037680A1 (en) 2012-08-06 2014-02-06 Glaxosmithkline Biologicals, S.A. Novel method
US9605276B2 (en) 2012-08-24 2017-03-28 Etubics Corporation Replication defective adenovirus vector in vaccination
EP2703483A1 (en) 2012-08-29 2014-03-05 Affiris AG PCSK9 peptide vaccine
CN104884081A (zh) 2012-12-05 2015-09-02 葛兰素史密丝克莱恩生物有限公司 免疫原性组合物
HRP20240996T1 (hr) 2013-03-13 2024-10-25 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Prefuzija rsv f proteina i njihova uporaba
BR112015023098A2 (pt) 2013-03-14 2017-07-18 Univ Jefferson agentes de infrarregulação do receptor de andrógeno e usos dos mesmos
EP3608332B1 (en) 2013-03-15 2022-06-01 GlaxoSmithKline Biologicals SA Vaccine against human rhinovirus
BR112015024860B1 (pt) 2013-03-28 2023-11-07 Access To Advanced Health Institute Polipeptídeo de fusão, polinucleotídeo isolado, composição compreendendo dito polipeptídeo, uso da dita composição para estimular uma resposta imune contra leishmania e método in vitro e kit de diagnóstico para detectar infecção por leishmania em uma amostra biológica
KR102039520B1 (ko) 2013-04-18 2019-11-01 이뮨 디자인 코포레이션 암 치료에 이용하기 위한 gla 단일요법
US9463198B2 (en) 2013-06-04 2016-10-11 Infectious Disease Research Institute Compositions and methods for reducing or preventing metastasis
US9919029B2 (en) 2013-07-26 2018-03-20 Inserm (Institut National De La Sante Et De La Recherche Medicale) Methods and pharmaceutical compositions for the treatment of bacterial infections
CA2919773A1 (en) 2013-08-05 2015-02-12 Glaxosmithkline Biologicals S.A. Combination immunogenic compositions
US9808472B2 (en) 2013-08-12 2017-11-07 Tokai Pharmaceuticals, Inc. Biomarkers for treatment of neoplastic disorders using androgen-targeted therapies
WO2015042373A1 (en) 2013-09-19 2015-03-26 Novavax, Inc. Immunogenic middle east respiratory syndrome coronavirus (mers-cov) compositions and methods
EP3146081B1 (en) 2014-05-19 2020-10-28 The Johns Hopkins University Methods for identifying androgen receptor splice variants in subjects having castration resistant prostate cancer
EP3154576A1 (en) 2014-06-13 2017-04-19 GlaxoSmithKline Biologicals S.A. Immunogenic combinations
LT3160500T (lt) 2014-06-25 2019-10-25 Glaxosmithkline Biologicals Sa Clostridium difficile imunogeninė kompozicija
EP3189069B1 (en) 2014-07-31 2024-10-23 UAB Research Foundation Apoe mimetic peptides and higher potency to clear plasma cholesterol
WO2016033114A1 (en) 2014-08-25 2016-03-03 The Johns Hopkins University Methods and compositions related to prostate cancer therapeutics
DK3233912T3 (da) 2014-12-19 2021-08-02 Regenesance B V Antistoffer, der binder human c6, og anvendelser deraf
WO2016112195A1 (en) 2015-01-09 2016-07-14 Etubics Corporation Methods and compositions for combination immunotherapy
EP3268037B1 (en) 2015-03-09 2022-08-31 Celldex Therapeutics, Inc. Cd27 agonists
US11149087B2 (en) 2015-04-20 2021-10-19 Etubics Corporation Methods and compositions for combination immunotherapy
WO2016180852A1 (en) 2015-05-12 2016-11-17 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for preparing antigen-specific t cells from an umbilical cord blood sample
CA2986961C (en) 2015-05-26 2023-07-25 Ohio State Innovation Foundation Nanoparticle based vaccine strategy against swine influenza virus
US20170226171A1 (en) * 2016-02-09 2017-08-10 Vaccinogen, Inc. Adenocarcinoma antigenic determinants and methods
JP2019511483A (ja) 2016-03-02 2019-04-25 ザ ボード オブ リージェンツ オブ ザ ユニバーシティー オブ テキサス システム 免疫療法のためのｓｔｉｎｇ活性化ナノワクチン
WO2017184619A2 (en) 2016-04-18 2017-10-26 Celldex Therapeutics, Inc. Agonistic antibodies that bind human cd40 and uses thereof
WO2017205225A2 (en) 2016-05-21 2017-11-30 Infectious Disease Research Institute Compositions and methods for treating secondary tuberculosis and nontuberculous mycobacterium infections
EP3463440A4 (en) 2016-05-27 2020-04-15 Etubics Corporation NEOEPITOP VACCINE COMPOSITIONS AND METHOD FOR USE THEREOF
WO2018053294A1 (en) 2016-09-16 2018-03-22 Infectious Disease Research Institute Vaccines comprising mycobacterium leprae polypeptides for the prevention, treatment, and diagnosis of leprosy
GB201616904D0 (en) 2016-10-05 2016-11-16 Glaxosmithkline Biologicals Sa Vaccine
WO2018104313A1 (en) 2016-12-07 2018-06-14 Glaxosmithkline Biologicals Sa Novel process
US11084850B2 (en) 2016-12-16 2021-08-10 The Pirbright Institute Recombinant prefusion RSV F proteins and uses thereof
GB201621686D0 (en) 2016-12-20 2017-02-01 Glaxosmithkline Biologicals Sa Novel methods for inducing an immune response
UA129243C2 (uk) 2017-04-19 2025-02-26 Інстітьют Фо Рісьорч Ін Біомедцін Антитіло, що зв'язується зі спорозоїтами p. falciparum
US20210187098A1 (en) 2017-04-28 2021-06-24 Glaxosmithkline Biologicals Sa Vaccination
GB201707700D0 (en) 2017-05-12 2017-06-28 Glaxosmithkline Biologicals Sa Dried composition
IE87414B1 (en) 2017-05-30 2023-07-19 Glaxosmithkline Biologicals Sa Novel methods for manufacturing an adjuvant
KR20240096685A (ko) 2017-06-15 2024-06-26 액세스 투 어드밴스드 헬스 인스티튜트 나노구조 지질 담체 및 안정적인 에멀션 그리고 이들의 용도
US20200254083A1 (en) 2017-06-16 2020-08-13 Glaxosmithkline Biologicals Sa Method of treatment
WO2019035963A1 (en) 2017-08-16 2019-02-21 Ohio State Innovation Foundation NANOPARTICLE COMPOSITIONS FOR VACCINES AGAINST SALMONELLA
CN111670044A (zh) 2017-12-01 2020-09-15 葛兰素史密丝克莱恩生物有限公司 皂苷纯化
WO2019147925A1 (en) 2018-01-26 2019-08-01 Nantcell, Inc. Compositions and methods for combination cancer vaccine and immunologic adjuvant therapy
US20190275134A1 (en) 2018-03-12 2019-09-12 Janssen Pharmaceuticals, Inc Vaccines against urinary tract infections
SG11202010011RA (en) 2018-04-17 2020-11-27 Celldex Therapeutics Inc Anti-cd27 and anti-pd-l1 antibodies and bispecific constructs
EP3581201A1 (en) 2018-06-15 2019-12-18 GlaxoSmithKline Biologicals S.A. Escherichia coli o157:h7 proteins and uses thereof
JP2021532764A (ja) 2018-07-31 2021-12-02 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム 抗原精製方法
EP3851120A4 (en) 2018-09-11 2022-04-27 Shanghai Public Health Clinical Center Immunogen for broad-spectrum influenza vaccine and application thereof
US20220133872A1 (en) * 2019-02-08 2022-05-05 University Of Florida Research Foundation, Inc. A monophosphoryl lipid-a liposome based cancer vaccine
BR112021024363A2 (pt) 2019-06-05 2022-03-22 Glaxosmithkline Biologicals Sa Purificação de saponina
WO2021014385A1 (en) 2019-07-24 2021-01-28 Glaxosmithkline Biologicals Sa Modified human cytomegalovirus proteins
EP3777884A1 (en) 2019-08-15 2021-02-17 GlaxoSmithKline Biologicals S.A. Immunogenic composition
MX2022002823A (es) 2019-09-09 2022-10-21 Glaxosmithkline Biologicals Sa Composiciones inmunoterapeuticas.
KR20220107166A (ko) 2019-10-02 2022-08-02 얀센 백신스 앤드 프리벤션 비.브이. 스타필로코커스 펩티드 및 사용 방법
WO2021122551A1 (en) 2019-12-19 2021-06-24 Glaxosmithkline Biologicals Sa S. aureus antigens and compositions thereof
EP4090363B1 (en) 2020-01-16 2024-09-04 Janssen Pharmaceuticals, Inc. Fimh mutant, compositions therewith and use thereof
US10953089B1 (en) 2020-01-27 2021-03-23 Novavax, Inc. Coronavirus vaccine formulations
WO2021178637A1 (en) 2020-03-05 2021-09-10 Iowa State University Research Foundation, Inc. IMMUNOGENIC AND VACCINE COMPOSITIONS AGAINST SARS-CoV-2
WO2021214766A1 (en) 2020-04-21 2021-10-28 Yeda Research And Development Co. Ltd. Methods of diagnosing viral infections and vaccines thereto
CN115485057A (zh) 2020-05-05 2022-12-16 葛兰素史克生物有限公司 微流体混合装置和使用方法
WO2021245025A1 (en) 2020-06-01 2021-12-09 Loop Diagnostics, S.L. Method and kit for the early detection of sepsis
US20230293659A1 (en) 2020-08-03 2023-09-21 Glaxosmithkline Biologicals Sa Truncated fusobacterium nucleatum fusobacterium adhesin a (fada) protein and immunogenic compositions thereof
AU2021337493A1 (en) 2020-09-04 2023-05-18 Access To Advanced Health Institute Co-lyophilized rna and nanostructured lipid carrier
EP4255919A2 (en) 2020-12-02 2023-10-11 GlaxoSmithKline Biologicals S.A. Donor strand complemented fimh
CA3203278A1 (en) 2020-12-09 2022-06-16 Glaxosmithkline Biologicals Sa Saponins
WO2022136563A2 (en) 2020-12-24 2022-06-30 Plant Bioscience Limited Methods and compositions
TW202241929A (zh) 2021-01-12 2022-11-01 美商詹森藥物公司 ＦｉｍＨ突變體、其組成物及其用途
JP2024506364A (ja) 2021-02-11 2024-02-13 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム Ｈｐｖワクチンの製造
WO2022208430A1 (en) 2021-04-01 2022-10-06 Janssen Pharmaceuticals, Inc. Production of e. coli o18 bioconjugates
MX2023011788A (es) 2021-04-09 2023-10-11 Celldex Therapeutics Inc Anticuerpos contra ilt4, anticuerpo biespecifico anti-ilt4/pd-l1 y usos de los mismos.
WO2023020993A1 (en) 2021-08-16 2023-02-23 Glaxosmithkline Biologicals Sa Novel methods
WO2023020992A1 (en) 2021-08-16 2023-02-23 Glaxosmithkline Biologicals Sa Novel methods
WO2023020994A1 (en) 2021-08-16 2023-02-23 Glaxosmithkline Biologicals Sa Novel methods
WO2023077521A1 (en) 2021-11-08 2023-05-11 Celldex Therapeutics, Inc Anti-ilt4 and anti-pd-1 bispecific constructs
EP4469078A1 (en) 2022-01-28 2024-12-04 GlaxoSmithKline Biologicals S.A. Modified human cytomegalovirus proteins
WO2023180677A1 (en) 2022-03-25 2023-09-28 Plant Bioscience Limited Biosynthesis
CA3253348A1 (en) 2022-06-15 2023-12-21 Glaxosmithkline Biologicals Sa ENZYMATIC MODIFICATION OF SAPONINS
GB202209588D0 (en) 2022-06-29 2022-08-10 Plant Bioscience Ltd Methods and compositions
IL319329A (en) 2022-09-09 2025-05-01 Access To Advanced Health Inst Immunogenic vaccine composition incorporating saponin
EP4658302A1 (en) 2023-02-02 2025-12-10 GlaxoSmithKline Biologicals S.A. Immunogenic composition
CN121219315A (zh) 2023-03-03 2025-12-26 塞德斯医疗公司 抗干细胞因子(scf)和抗胸腺基质淋巴细胞生成素(tslp)抗体及双特异性构建体

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2160326B1 (cg-RX-API-DMAC10.html) * 1971-11-19 1975-02-07 Anvar
US4338334A (en) * 1977-12-29 1982-07-06 Merck & Co., Inc. 1-[4-(4-Sulfanilyl)phenyl] urea and derivatives in compositions and methods of treating rheumatoid arthritis and immune complex diseases
US4307229A (en) * 1979-11-07 1981-12-22 Avraham Liav 6,6'-Diesters of trehalose and process for the synthesis thereof
US4436728A (en) * 1982-05-26 1984-03-13 Ribi Immunochem Research, Inc. Refined detoxified endotoxin product
US4436727A (en) * 1982-05-26 1984-03-13 Ribi Immunochem Research, Inc. Refined detoxified endotoxin product
US4505903A (en) * 1982-06-30 1985-03-19 Ribi Immunochem Research, Inc. Pyridine soluble extract of a microorganism
US4606918A (en) * 1983-08-22 1986-08-19 Syntex (U.S.A.) Inc. Polyoxypropylene-polyoxyethylene block polymer based adjuvants
US4663306A (en) * 1983-09-23 1987-05-05 Ribi Immunochem Research, Inc. Pyridine-soluble extract-refined detoxified endotoxin composition and use

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008214266A (ja) * 2007-03-05 2008-09-18 Dainippon Sumitomo Pharma Co Ltd 細菌細胞壁骨格成分の製造方法
JP2013531677A (ja) * 2010-07-02 2013-08-08 インターベツト・インターナシヨナル・ベー・ベー エーリキア・カニスに対するワクチンおよび関連する方法

Also Published As

Publication number Publication date
JPH0575731B2 (cg-RX-API-DMAC10.html) 1993-10-21
GB8822749D0 (en) 1988-11-02
US4877611A (en) 1989-10-31
GB2210557A (en) 1989-06-14
CH678492A5 (cg-RX-API-DMAC10.html) 1991-09-30
FR2620941A1 (fr) 1989-03-31
IT1226861B (it) 1991-02-19
GB2210557B (en) 1991-11-13
DE3833319A1 (de) 1989-04-13
BE1001634A4 (fr) 1990-01-02
NL8802393A (nl) 1989-04-17
DE3833319C2 (cg-RX-API-DMAC10.html) 1992-06-11
IT8822145A0 (it) 1988-09-30
FR2620941B1 (fr) 1990-08-10
CA1333152C (en) 1994-11-22

Similar Documents

Publication Publication Date Title
JPH01163130A (ja) 腫瘍抗原およびアジュバントを含有するワクチン
CA1217136A (en) Refined detoxified endotoxin product
KR870000842B1 (ko) 정제 해독된 내독소 및 그의 제조방법
Werner et al. Immunostimulating agents: what next? A review of their present and potential medical applications
US4866034A (en) Refined detoxified endotoxin
US4505900A (en) Refined detoxified endotoxin product
US4435386A (en) Refined detoxified endotoxin product
KR870000843B1 (ko) 피리딘 가용성 추출물의 제조방법
Weiss MER and other mycobacterial fractions in the immunotherapy of cancer
EP2241324A1 (en) Composition for use in a method for treating cancer.
US4505899A (en) Refined detoxified endotoxin product
DE60031100T2 (de) Hapten modifizierte tumorzellen und verfahren zur herstellung und deren verwendung
US4504473A (en) Pyridine soluble extract of a microorganism
FI65370C (fi) Foerfarande foer framstaellning av ett fast farmaceutiskt preparat
Butler et al. Combined immunostimulation in the prevention of tumor take in mice using endotoxins, their derivatives, and other immune adjuvants
CA1202903A (en) Stable composition and preparation thereof
Liu et al. Virulizin-2gamma, a novel immunotherapeutic agent, in treatment of human pancreatic cancer xenografts.
EP0615758B1 (en) Anti-tumor vaccines
GB2122897A (en) Treatment of cancer with microorganism obtained products
CN119405804A (zh) 一种无需抗原的生物可降解纳米制剂及其应用
Butler Enhancement of nonspecific resistance to tumor by endotoxin

Legal Events

Date Code Title Description
R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20081021

Year of fee payment: 15

EXPY Cancellation because of completion of term